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Background: There is a need for more resources to support the cognition and quality of life (QoL) of people with dementia. The
individual Cognitive Stimulation Therapy application (iCST app) aims to provide cognitive stimulation and social interaction to
people with dementia and carers through interactive touch-screen technology. It has been developed according to the principles
of CST and iCST which have previously shown to improve the cognition and QoL of people with dementia, and to benefit the
relationship between the person with dementia and carer, while improving quality of the carer’s life. This study aims to evaluate
the feasibility of conducting a full-scale, randomized controlled trial (RCT) with the iCST app.
Objective: To evaluate the feasibility of conducting a full-scale RCT with the iCST app compared to a treatment as usual (TAU)
control group.
Methods: A multi-centre, pragmatic, single blind, feasibility RCT with a treatment as usual (TAU) control group. This study
aims to recruit 60 people with mild to moderate dementia and their informal carers as dyads. Both parties must be able to provide
informed consent and participate in the intervention. Dyads will complete a baseline assessment which will include cognition and
QoL measures, and will subsequently be randomized (1:1) to the iCST app intervention in addition to usual care, or to usual care
only. All participants will be followed-up at 5 weeks and 11 weeks post-baseline. A range of feasibility outcomes will be
assessed including recruitment and retention rates, intervention fidelity and usability, and acceptability of the outcome measures.
A sample of the experimental group will be invited to a semi-structured post-trial interview to further examine the experience of
using the iCST app.
Results: Recruitment began in November 2018 with 43 dyads recruited from primary and secondary care settings. Participants
were randomized to the iCST app (n = 21) or TAU control group (n = 22) with a relatively low attrition rate throughout the study
(n = 2). Dementia support groups and (online) research databases led to the majority of the referrals for the study.
Conclusions: This study will investigate whether it is feasible to conduct a full-scale RCT to evaluate the clinical effectiveness
of the iCST app in comparison to usual care alone. In addition, it will further examine the usability of the iCST app. The data
will provide information on potential modifications to be made to the intervention, study design, and study process. Clinical
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Abstract
Background: There is a need for more resources to support the cognition and quality of life (QoL) of
people with dementia. The individual Cognitive Stimulation Therapy application (iCST app) aims to
provide cognitive stimulation and social  interaction to people with dementia and carers through
interactive touch-screen technology. It has been developed according to the principles of CST and
iCST which have previously shown to improve the cognition and QoL of people with dementia, and
to benefit the relationship between the person with dementia and carer, while improving quality of
the carer’s life. This  study aims  to evaluate the feasibility  of conducting a full-scale, randomized
controlled trial (RCT) with the iCST app.
Objective: To evaluate the feasibility of conducting a full-scale RCT with the iCST app compared to a
treatment as usual (TAU) control group.
Methods: A multi-centre, pragmatic, single blind, feasibility RCT with a treatment as usual (TAU)
control  group.  This  study  aims  to  recruit  60  people  with  mild  to  moderate  dementia  and  their
informal carers as dyads. Both parties must be able to provide informed consent and participate in
the intervention. Dyads will complete a baseline assessment which will include cognition and QoL
measures, and will subsequently be randomized (1:1) to the iCST app intervention in addition to
usual care, or to usual care only. All participants will be followed-up at 5 weeks and 11 weeks post-
baseline. A range of feasibility outcomes will be assessed including recruitment and retention rates,
intervention  fidelity  and  usability,  and  acceptability  of  the  outcome measures.  A sample  of  the
experimental group will be invited to a semi-structured post-trial interview to further examine the
experience of using the iCST app. 
Results: Recruitment began in November 2018 with 43 dyads recruited from primary and secondary
care settings. Participants were randomized to the iCST app (n = 21) or TAU control group (n = 22)
with a relatively low attrition rate throughout the study (n = 2). Dementia support groups and (online)
research databases led to the majority of the referrals for the study. 
Conclusions: This study will investigate whether it is feasible to conduct a full-scale RCT to evaluate
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the clinical effectiveness of the iCST app in comparison to usual care alone. In addition, it will further
examine the usability of the iCST app. The data will provide information on potential modifications to
be made to the intervention, study design, and study process. 
Trial registration: ClinicalTrials.gov, NCT03282877. Registered on 19 July 2017.
Keywords 
Dementia, Cognitive Stimulation Therapy, touch-screen technology, feasibility trial.
Background 
Dementia poses a significant challenge to individuals in staying mentally stimulated and engaged.
This is further exacerbated given the lack of resources to support the cognition and quality of life
(QoL) for  people with dementia.  Cognitive Stimulation Therapy (CST) is a non-pharmacological
treatment  strongly  recommended  by  the  National  Institute  for  Health  and  Care  Excellence.  A
previous randomized controlled trial (RCT) showed it can benefit the cognition and QoL of people
with  dementia  [1].  Individual  CST  (iCST)  is  delivered  by  a  carer  at  home  and  has  shown
improvements in the relationship quality between the person with dementia and carer, and the QoL
of carers [2]. Touch-screen technology can improve accessibility to interventions by offering these
on devices such as mobile phones and tablets. A systematic review has shown that touch-screen
interventions with sound designs and tailored content can improve the well-being of people with
dementia [3]. 
 Researchers have developed a novel, touch-screen iCST application (app) which aims to
offer cognitive stimulation to people with dementia at home using touch-screen technology. It  is
hoped that the iCST app may produce combined benefits of engaging in CST, iCST and touch-
screen technology. The app’s development followed the Medical Research Council  Framework for
developing  complex  interventions  and  the  Centre  for  eHealth  Research  roadmap  [4,  5].  This
included extensive reviews of CST and iCST materials, and end-user involvement through informal
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consultations, focus groups, individual interviews, and usability questionnaires [6]. The next stage of
development encompasses this feasibility RCT. Findings from this study will inform whether a large-
scale RCT evaluating the clinical effectiveness of the iCST app is indicated by investigating relevant
study parameters related to the study design and process. 
Aims 
The aims of this feasibility RCT are to: 
(1) to evaluate the feasibility of conducting a full-scale RCT with the iCST app compared to a
treatment as usual (TAU) control group and,
(2) to assist the development of a protocol for a full-scale trial, including power analysis. 
Methods
The 26-item Consolidated Standards of  Reporting Trials (CONSORT) checklist  of  information to
include when reporting feasibility trials will be used for this study to ensure all the necessary and




This study is a multi-centre, pragmatic, single blind, feasibility RCT with an allocation ratio of 1:1.
People with dementia and carers will be recruited as dyads and will be randomized to either the
experimental (completing 2 to 3, 30-minute iCST app sessions per week) or the TAU control group
for 11 weeks. Dyads will complete the baseline assessment prior to randomization and hereafter,
the first follow-up (FU1) will be completed 5 weeks post-baseline, and the second follow-up (FU2)
11 weeks post-baseline (Figure 1). A sample of the experimental group will be invited for a semi-
structured post-trial  interview to gain insights in  the acceptability  of  the iCST app including the
experience of using the app, and any facilitators and barriers for implementation in daily life.  
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Participants
Recruitment  started  on  1  November  2018  and  will  take place  in  5  secondary  care  settings  in
England:  Derbyshire  Healthcare  NHS  Foundation  Trust,  Leicestershire  Partnership  NHS  Trust,
Lincolnshire  Partnership  NHS Foundation  Trust,  Northamptonshire  Healthcare  NHS Foundation
Trust,  and  Nottinghamshire  Healthcare  NHS  Foundation  Trust.  In  addition,  participants  will  be
identified  through a  variety  of  settings  including general  practitioner  (GP)  practices,  community
mental health teams, memory clinics, care homes, memory cafes, support groups, and voluntary
sector organisations such as the Alzheimer’s Society. Remote recruitment will include registration on
the website Join Dementia Research (JDR), publicizing the study using social media platforms such
as Twitter, and the distribution of information leaflets and posters to organisations and professionals
involved in the identification of possible participants.  
Eligibility Criteria 
The sample will include people with mild to moderate dementia and their informal carers (relatives
or  friends).  The  inclusion-  and  exclusion  criteria  were  adapted  from  previous  CST  and  iCST
research [1, 2] and include the following:
Person with dementia: 
 Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for dementia
[8].    
 Score 10 or above on the Mini Mental State Examination (MMSE) [9] or score of 16 or above
on the Montreal Cognitive Assessment [10] where available.
 Some ability to communicate and understand (eg, ability to give informed consent).
 Ability to speak and understand English.
 See/hear well enough to participate.
 No major physical illness or disability affecting their participation.
 Age range: 50 years – no maximum age limit.
 Availability of a touch-screen tablet for the person with dementia and carer.
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 Availability of a carer (or relative/friend) to participate in the activities.
Carer:
 Minimum age: 21.
 Ability to speak and understand English.
 See/hear well enough to participate.
 No major physical illness or disability affecting their participation.
Exclusion criteria person with dementia and carer:
 Concurrent participation in any other interventional study for people with dementia/carers.
Sample  Size
A formal sample size calculation is not appropriate for a feasibility trial. A previous audit of trials
registered in the Clinical Research Network (CRN) database in the UK found that most feasibility
and pilot trials had a median of 30 or 36 participants per arm and the researchers recommend an
upper limit of 60 participants for a feasibility trial [11]. Therefore, a target of 60 dyads is set for this
study leading to 30 dyads per treatment arm.
Procedure  
Screening  for  Eligibility
Anticipating logistical support from the National Institute for Health Research CRN East Midlands, it
is expected that staff members at each research site will check the eligibility of referrals received
from clinicians and staff at the recruitment sources. Participants fulfilling the inclusion criteria will be
sent a participant information sheet containing full details about the study. If the dyad is interested in
participating,  they  will  be  recruited  into  the  trial  and  a  date  for  the  baseline  assessment  and
consenting will be set by the CRN staff member.
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Recruit N = 60 dyads screened by
inclusion  criteria:  mild/moderate
dementia,  MMSE  10+,  some
ability  to  communicate,  touch-
screen tablet, carer
Baseline data collection (incl.
informed consent)
Remote randomization
n = 30 allocated to iCST app
group
n = 30 allocated to TAU
control group
iCST app installation visit
Outcome measures at 5 weeks post baseline (FU1) 
Outcome measures at 11 weeks post baseline (FU2) 
Figure  1. Flow  diagram  of  iCST  app  feasibility  RCT.
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Randomization
Randomization will take place after consent and the baseline assessment using an online, central
randomization  service  called  Sealed  Envelope  (https://www.sealedenvelope.com/).  Block
randomization will be employed with block sizes of 4 to 6 (randomly varied and generated by Sealed
Envelope)  which  is  a  useful  method  for  small  sample  sizes  to  allocate  an  equal  number  of
participants  to  each  treatment  arm  [12].  The  researcher  at  the  local  site  will  perform  each
randomisation  using  the  participant  identification  code  of  the  person  with  dementia  only.  The
allocation to the experimental or TAU control group will automatically apply to the carer as well.
Dyads will be informed of their allocation outcome over the telephone and, if necessary, a visit will
be arranged for dyads in the experimental group to install the iCST app.
Blinding
 
The trial will include both blinded and unblinded researchers at each local site. It is not possible to
blind  the  participants  to  their  treatment  arm  as  the  iCST  app  is  a  non-pharmacological
intervention. However, each study site will include at least one researcher kept in ignorance of
study allocations. The baseline assessment can be performed by either researcher.  However,
FU1 and FU2 will be completed only by the researcher who is unaware of the randomization
outcome for each dyad. If disclosure does occur, this will be recorded by the visiting researcher
along with details on how it occurred. The unblinded researcher will perform the randomization,
communicate the outcome with the participants, and for the experimental group, install the iCST
app,  provide  weekly  telephone  support  calls,  and  complete  the  usability  and  acceptability
questionnaire at the end of the study. Furthermore, the unblinded researcher will not be informed
about the results of the assessments. 
The  Intervention:  iCST  Application
Participants in the experimental group will use the iCST app (prototype v3.0) over 11 weeks post-
baseline. The content of the app was modified from the paper-based iCST manual including the
principles, themes, and activities [2], and was also based on consultations and qualitative research
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with people with dementia, carers, and the software development company [6]. The iCST app is a
one-to-one,  carer-led,  home-based  program  of  structured  cognitive  stimulation  for  people  with
dementia but delivered on a touch-screen tablet. It includes 21 activities consisting of both game-
like, interactive features such as audio-visual stimuli, and discussion questions (Table 1). This was
to offer mental stimulation through the content on the app but also through conversation. 
Table  1. List  of  the  iCST  app  activities  (prototype  v3.0)
Game Discussion Game and discussion
Being Creative Past Events Sounds
Spaceman Useful Tips Odd one Out
Trivia Quiz My Life The Price is Right
Word Search Arts Globe Trotter
Sudoku Old Wives’ Tales Food
Being Active Toys Are Us In Pairs
Brainstorm Sayings
ISpy
In addition, the app includes several other features such as a short introduction section explaining
the background and key tips for using the app, a home screen which features completed activities,
and a choice from 2 levels. Level 2 contains either more challenging content or different questions
from Level 1, and it is up to the participants to determine which level they feel more comfortable with
for each activity. Figure 2 contains screenshots of the iCST app. Considering previous CST and
iCST research and findings from the development work, it is recommended that participants use the
app for 2 or 3 times a week for 30 minutes [2]. Participants are free to spend more time on the app if
they wish, and this will be recorded during the weekly telephone calls. 
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Figure 2. Screenshots of the iCST app: home screen (left) and Sounds activity (right).
Training and Adherence
 
In  order  to  ensure  treatment  integrity  for  all  participants,  individual  study  sites  will  receive  a
demonstration of the iCST app along with training in its installation and use prior to the start of
recruitment.  Dyads  in  the  experimental  group  will  receive  an  in-home visit  from the  unblinded
researcher who will install the app and explain how it works using a short, supplementary document
containing  instructions  with  screenshots  of  the  app.  Furthermore,  all  dyads  will  receive  weekly
telephone support calls from the same unblinded researcher in order to monitor adherence but also
to track overall progress and any challenges or technical difficulties with using the iCST app. Phone
calls will be completed with the carer and all questions will be included on a standardised telephone
sheet. The questions relate to general experience, amount of sessions completed in a week (on
average), amount of time spent per session (on average), enjoyment, and any likes/dislikes. Any
reasons for not being able to use the iCST app over the week will also be recorded on the telephone
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sheet.  
Treatment as Usual (TAU) 
The control group will consist of TAU group and will not receive any additional interventions.  TAU
groups are typically used to compare experimental interventions to care which participants already
receive in practice [13]. Therefore, the TAU control group will enable us to compare the effects of
the iCST app with the natural progression of people with dementia under conditions of usual care. 
 The treatments and services which are already available to people with dementia and their
carers randomized to the TAU control group, may differ between and within recruitment sites for
instance,  regarding  acetylcholinesterase  inhibitors  (AchEIs)  or  being  involved  in  some  form  of
cognitive  stimulation  already.  However,  it  is  unlikely  that  people  have  access  to  computerized
versions of iCST since these do not exist to the best of our knowledge. The visiting researcher will
record any current participation with CST groups and use of AchEIs at the baseline assessment. 
Outcomes
Feasibility Outcomes
In order to determine the feasibility of conducting a full-scale RCT with the iCST app in the future,
this  trial  will  investigate  key  feasibility  aspects  including  the  rates  of  recruitment,  screening,
randomization, and retention using enrolment logs [4]. Acceptability of the outcome measures will
be evaluated by assessing the completion rates, and the acceptability and fidelity of the iCST app
will be evaluated through weekly telephone support calls, analytics, and a usability and acceptability
questionnaire. It is expected that >75% of the participants in the experimental group will need to
complete the recommended minimum of 2 activities on average every week for the iCST app to be
considered feasible. This benchmark has been adopted based on work in some previous feasibility
trials  including  psychological  treatments  where  benchmarks  for  successful  adherence  ranged
between 75% to 80% [14, 15].
Clinical Outcomes
Previous CST and iCST research, and the Interdem consensus statement on outcome measures for
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dementia  informed the outcome measure selection for this study [16]. Key outcome measures of
interest for the person with dementia are cognition and QoL as previous CST research has shown
improvements in these domains [1]. For the carer, the key outcome measure is QoL as previous
iCST  research  has  shown  to  improve  the  QoL of  carers  [2].  This  study  additionally  includes
technology-related scales to assess usability and acceptability of the iCST app and computer use
self-efficacy. All assessments will take place in the homes of the participants. Wherever possible, 2
researchers  will  visit  the  participants  in  order  to  interview the person with  dementia  and carer
separately. It will be possible to conduct the assessments over 2 days in case of fatigue or other
practical issues such as lack of time. As in the previous iCST trial, FU1 at 5 weeks will be included
to safeguard data against loss to follow up [2]. FU2 will take place at 11 weeks post-baseline as this
should be the point that participants in the experimental group will have completed each activity on
the iCST app. 
Outcome  Measures  for  Person  With  Dementia
 Cognition measured using the Alzheimer’s Disease Assessment Scale-Cognition [17]. 
 QoL measured using the Quality of Life – Alzheimer’s Disease (QoL-AD) questionnaire [18].
Carers will complete the family version of the QoL-AD.
 Health-related QoL measured using the  EuroQoL five dimensions (EQ-5D) questionnaire
[19].
 Relationship quality measured using the  Quality of the Carer Patient Relationship (QCPR)
questionnaire [20].
 Symptoms of depression measured using the Cornell Scale for Depression in Dementia [21].
Carers will complete this questionnaire as an informant. 
 Behavioral disturbances measured using the Neuropsychiatric Inventory and will be rated by
the carer only [22]. 
 Functional abilities measured using the Bristol Activities of Daily Living Scale [23] and rated
by the carer only.
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Outcome  Measures  for  Carers
 
 Health-related QoL measured using the EQ-5D questionnaire [19]. 
 Anxiety and depression measured using the Hospital Anxiety and Depression Scale [24]. 
 Relationship quality measured using the QCPR questionnaire [20].
Technology  Scales  for  People  With  Dementia  and  Carers  
 Self-efficacy beliefs in computer/tablet use measured at baseline only using the Computer
User Self-Efficacy scale [25]. 
 Usability and acceptability of the iCST app measured at FU2 and among the experimental
group only using the Questionnaire of Usability and Acceptability (CUA) [26]. 
Post-trial Interviews 
A small proportion of dyads in the experimental group will be invited to participate in joint, semi-
structured interviews. The purpose of the interviews is to gain additional information on the layout
and content of the iCST app, the overall experience of using it as a dyad, and any practicalities
surrounding its use in daily life. The interview serves as a complementary data collection method to
the weekly telephone support calls and the usability questionnaire as a semi-structured interview
generates more in-depth data that otherwise cannot be accessed through quantitative methods only
[27]. A discussion guide will be developed including the key areas mentioned before to help guide
the interview. Each dyad in the experimental group will be invited to participate in the interview upon
completion of the study. If they are interested, further details for the person with dementia and carer
will be sent. If a dyad agrees to participate, a date for the interview will be set. All interviews will take
place  in  the  home  of  the  participants.  Written  informed  consent  will  be  obtained  from  both
participants  by  the  unblinded  researcher.  The  data  will  be  audio-recorded,  transcribed,  and
subsequently stored on a password protected computer at the University of Nottingham. 
End of Study
FU2 constitutes the end of the study for participants. At this final visit by the blinded researcher, all
participants will be given a £10 Apple or Google Play store voucher in order for them to download
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the  iCST app  once  it  has  been  released  on  the  app  stores.  This  will  be  accompanied  by  an
instructional document on how to redeem your voucher and a newsletter containing information on
what will happen next such as making improvements to the app, and analyzing and disseminating
the results.    
Ethical Considerations
Ethical approval has been obtained from the Yorkshire and the Humber – Bradford Leeds Research
Ethics  Committee  and  NHS  Health  Research  Authority  in  March  2018  (reference  number
17/YH/0405).
Consent
People with mild to moderate dementia will be recruited in the study and are expected to be able to
give informed consent  for participation provided that appropriate care is taken in explaining the
research and sufficient time is allowed for them to reach a decision. Written informed consent will be
taken at baseline from both the person with dementia and carer. Since the intervention requires joint
participation,  it  is  likely  that  both  participants  will  consult  each  other  in  making  their  decision.
Therefore,  it  is  possible  that  any  individual  participant’s  decision  to  either  participate  or  not
participate with the research may be influenced by the other participant. However, it is important that
individual participants are not forced to make a decision against their will and the researcher will
spend as much time as necessary in speaking to the participants individually about the research. It
will  be made clear to both people with dementia and carers that no disadvantage will accrue in
terms of the current care they receive or any future research opportunities, if they choose not to
participate or withdraw from the study. The consent form will be signed and dated by the participant
and the researcher before they enter the study. One copy will be given to the participant and one will
be retained at the local study site. 
Adverse Events
Previous work with CST, MCST, and iCST has not documented any harmful side effects nor any
serious adverse events from participating in the intervention activities [1, 2, 28]. Given that the iCST
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app is based on the principles of CST and follows a comparable structure to iCST, it is expected that
this study will  not lead to harmful side effects for either the person with dementia or the carer.
Researchers will be made aware of any adverse events during follow-up assessments or the weekly
telephone support calls. The trial manager and chief investigator of the study will be informed in
case of any adverse events who will then assess the severity of the adverse event. Serious adverse
events  include  events  such  as  death,  illness  related  to  a  previous  health  condition,  or
hospitalisation. 
Data Security and Entry
Each  study  site  will  create  their  own  password-protected  spreadsheet  containing  participant
identifiable information and allocation outcome for the dyad. This spreadsheet can only be accessed
through a secure NHS trust computer. After collection of the data from each site, the data will be
stored in a secure cabinet at the University of Nottingham. Identifiable information including the
consent forms will be kept in a separate, locked cabinet. After reviewing the data and checking the
scoring, it will be entered manually into SPSS version 25 for Windows, which will be used for all the
analyses.
Statistical Analyses 
Key feasibility outcomes will be reported through frequencies and include the number of participants
screened, recruited, randomized, and retained through the duration of the trial. Adherence to the
intervention will be assessed by calculating the average number of iCST app activities completed by
the dyad logged in the weekly telephone calls. The usability and acceptability of the iCST app will be
further investigated by examining data from the weekly telephone calls, post-trial interviews, and by
calculating  scores  on  the  CUA  with  higher  scores  indicating  higher  levels  of  usability  and
acceptability.  Data  from  the  post-trial  interviews  will  be  coded  and  summarised  and  may  be
analysed thematically with specialised software if sufficient data has been obtained to reach data
saturation  [29].  Lastly,  outcome  measures  will  be  assessed  for  appropriateness  by  calculating
missing data rates within the measures and across the follow-ups. 
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 As this is a feasibility trial and null hypothesis significance testing is inappropriate due to a
likely  lack of  power to detect  significant  effects of  the intervention [30-32],  analyses will  mainly
include descriptive  statistics  computed for  each group and outcome measure including means,
standard deviations, 95% confidence intervals and effect sizes [7, 33]. However, in order to compare
the outcomes on each of the questionnaires between the two groups, an analysis of covariance will
be undertaken which will help to better understand any trends in the data. All analyses will be based
on the intention-to-treat principle in that all available data will be included in the analyses. Rules for
missing  data  will  be  adapted  from the  main  iCST trial  2.  Data  will  not  be imputed  if  outcome
measures or assessments are missing in full, and imputation (using pro-rating) will only be used
when fewer than 20% of cases are missing on any given measure. 
Results
Recruitment
A total of 384 dyads have been approached or referred across 4 research sites and, of these, 43
dyads have been consented, gave completed the baseline assessment and were randomized to
either the iCST app or TAU control group. Table 2 includes the response rates and the total numbers
of  participants lost  before randomization accompanied by reasons for  loss.  Most  frequently,  the
reason for not recruiting a dyad to the trial was unknown as not all sites registered dyads’ reasons
for not participating with the study (eg, when visiting support groups in particular). In most other
cases, the lack of having a correct device for the study and the remaining study exclusion criteria
led to dyads being ineligible.  Participants who did  not  have the correct  device,  often did  have
access to technology such as personal computers, laptops, and mobile phones but not a device
compatible with the iCST app such as a tablet with iOS version 10 or Android version 4.4.2.
Table 2. Response rates and loss of participants prior to randomisation.
Reason Total (%)
Total approached/referred 384
Reason unknown or not disclosed 100 (26)
Exclusion criteria applied 90 (23)
Lack of availability correct device 80 (21)
Does not wish to take part 52 (14)
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Dyad approached has not responded 14 (4)
Not interested in using technology 5 (1)
Total  lost  between  approach/referral  and
randomization
341 (89)
Total number randomized 43  (11)
Participants were most often referred from or approached through dementia support groups (n =
162), JDR (n = 76), the site’s own research database (n = 69), or clinicians working in community
mental health teams or memory assessment services (n = 43). A small proportion of participants
were  approached  through  their  GP (n  =  13)  or  care  home promotion  (n  =  2),  and  one  other
participant was referred through a leaflet advertising the study. For 18 participants, the source of
referral or approach was unknown.
Participant  Flow  and  Retention  Rates
Figure  3  shows  the  participant  flow through  the  feasibility  trial  along  with  treatment  allocation,
number of withdrawals, and non-completion of either FU1 or FU2 per allocation group [7]. Block
randomization led to an equal distribution of participants across the treatment groups with 21 dyads
randomized to the iCST app group and 22 dyads randomized to the TAU control group. One dyad in
the  experimental  group  was  not  able  to  access  the  iCST app. All  participants  accepted  their
allocation outcome to either the iCST app or TAU control group and no dyads dropped out after
learning their randomization results. Furthermore, retention rates were high with only 2 dyads from
the experimental group withdrawn from the study. 
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*dyad  who  did
not  receive  the  intervention  in  the  experimental  group  was  subsequently  withdrawn  from  the  study.
Figure 3. CONSORT flow diagram: participant flow through feasibility trial.  
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Baseline Demographic Data
Tables 3 and 4 show the demographic information of people with dementia and carers. People with
dementia overall had a mean age of 73.05 years, and the majority of people with dementia were
male (n = 29), married (n = 34) and lived at home with their spouse or partner (n = 36). Half of the
people with dementia had no educational qualifications (n = 11) or had left school after their O-
Levels/GCE (n = 10).  Most people with dementia were taking AchEIs at the time of the baseline
assessment (n = 30) with an almost equal distribution across the iCST app (n = 16) and TAU control
group (n = 14). Lastly, the majority of people with dementia were not involved in any CST groups at
the time of  the study (n = 35).  Data for  7 people with dementia  was missing on at  least  one
demographic. 
Table 3. Demographics of people with dementia.
Total iCST app TAU 
Characteristic
Age in years: mean, SD 73.05,  8.41
(range: 50-89)
73.43, 7.81 72.65, 9.20
Male (%) 29 (67) 13 (62) 16 (73)
Ethnicity white (%) 42 (98) 20 (95) 22 (100)
Relationship  with  carer:
married (%)
34 (81) 18 (86) 16 (76)
Lives with spouse/partner (%) 36 (86) 18 (86) 18 (86)
Education: no qualifications or
School Leaver O-Levels/GCE
(%)
21 (50) 12 (57) 9 (43)
Taking AchEI medication (%) 30 (75) 16 (80) 14 (70)
The mean age of carers was 66.21 years and the majority of carers were female (n = 33) and in
terms of educational qualifications had either left school after their O-Levels/GCE (n = 14) or had a
BSc/BA degree (n = 10). Data was missing for 5 carers on at least one demographic. For both
people with dementia and carers, the sample was predominantly white with only one person with
dementia from Asian descent. One carer preferred not to disclose their ethnicity.
A total of  34 spousal dyads participated with the study and the non-spousal dyads consisted of
partners (n = 2),  children (n = 3)  or  the son/daughter-in-law (n = 1)  of  the person.  Two dyads
identified their relationship as ‘other’.
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Table 3. Demographics of carers.
Total iCST app TAU
Characteristic
Age in years: mean, SD 66.21,  12.11
(range: 27-83)
68.21, 9.90 64.30, 13.88
Female (%) 33 (77) 16 (76) 17 (77)
Ethnicity white (%) 42 (100) 21 (100) 21 (100)
Education:  School  Leaver
O-  Levels/GCE or  Higher
Education (BSc/BA) (%)
24 (59) 11 (52) 13 (65)
Discussion
Overview  
The iCST app is the first computerized version of iCST which can be used on touch-screen tablets
by people with dementia and their carers. It aims to provide mental stimulation and to stimulate
conversation  between dyads through the use of  interactive  touch-screen technology.  Based on
previous research, it is expected that regular use of the iCST app could potentially lead to improved
cognition and QoL for the person with dementia and carer. This is an innovative feasibility RCT
which sets out to evaluate the feasibility of conducting a full-scale RCT with the iCST app compared
to a TAU control group, and to assist the development of a protocol for a full-scale trial. A range of
data will be collected on relevant study-related aspects for a potential full-scale RCT including the
study design and process,  and the feasibility  and usability  of  the  iCST app.  Data  collection  is
supported by a mixed methods approach where quantitative data from questionnaires and analytics
will  be  complemented by  qualitative  data from telephone calls  and interviews with  people  with
dementia and carers.
 Preliminary findings indicate that recruitment for the study is feasible but certain challenges
related  to  the technology-related  inclusion  criteria  have  been  identified  (eg,  lack  of  compatible
touch-screen tablet for iCST app). Dementia support groups, JDR, and the local research databases
have  generated  the  majority  of  referrals  for  this  study,  and  may  prove  to  be  most  useful  for
recruitment  in  a  larger  study.  Referral  through  community  mental  health  teams  and  memory
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assessment services could be improved by more frequent contact and visits to such sites. Findings
also suggest that allocation outcome following randomisation is acceptable to participants with a
relatively low attrition rate across the two groups. The findings from this feasibility RCT will be used
to draw recommendations in terms of conducting a full-scale trial and determine which modifications
are necessary.  This  will  be done using the Acceptance Checklist  for  Clinical  Effectiveness Pilot
Trials  which consists  of  several  trial  components ranging from trial  design and interventions  to
randomization and data procedures [34]. It will be used to determine which components of the trial
will need amendments and how this can be achieved. In addition to a large-scale RCT with the iCST
app, other research activities could consist of an implementation study which would investigate the
cost-effectiveness and also the accessibility of the iCST app among people with dementia from
varying backgrounds. This could include consultation work with people with dementia and carers in
order to explore facilitators and barriers towards accessing technology, the iCST app and its use. 
Limitations
 
This is a national,  small-scale study with a limited amount of study sites and participants which
means that formal effectiveness of the iCST app cannot be evaluated. However, the study scale and
smaller  sample  size  is  appropriate  for  the  purpose  of  a  feasibility  RCT.  The  iCST app  is  only
compatible  with  certain  touch-screen  tablets  and  software  versions  which  has  proved  to  be  a
challenge  to  recruitment  for  all  study  sites.  Furthermore,  reasons  for  referral  loss  were  often
unknown as not all study sites registered reasons why potential participants were not recruited to
the study. Therefore, there is a need for improved monitoring to ensure how referral loss can be
minimized for a future full-scale trial. 
Conclusion  
This study will  give insights in  the feasibility  of  conducting a full-scale RCT with the iCST app
compared to a TAU control group. Preliminary results show that recruitment is feasible despite some
challenges  related  to  the  technology-related  inclusion  criteria.  Furthermore,  randomization
measures are adequate and attrition is low throughout the study. The full results of this feasibility
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RCT including data on the intervention in terms of usability and adherence, and outcome data are
expected in early 2021. These results will inform whether a full-scale RCT is feasible and which
modifications to the study design and process, and intervention are needed.  
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CONSORT: Consolidated Standards of Reporting Trials
CRN: Clinical Research Network
CST: Cognitive Stimulation Therapy
CUA: Questionnaire of Usability and Acceptability




iCST: individual Cognitive Stimulation Therapy
JDR: Join Dementia Research 
MMSE: Mini Mental State Examination
QCPR: Quality of the Carer Patient Relationship
QoL: Quality of Life
QoL-AD: Quality of Life – Alzheimer’s Disease 
RCT: Randomized Controlled Trial
TAU: Treatment as Usual
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